Curaleaf Holdings (CURLF) Income from Non-Controlling Interests (2020 - 2026)
Curaleaf Holdings (CURLF) recorded quarterly Income from Non-Controlling Interests of -$16000.0 in Q1 2026, down 100.0% quarter-over-quarter from $2.2 billion in Q4 2025, and down 101.96% on a YoY basis from $817000.0 in Q1 2025.
Curaleaf Holdings (CURLF) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Curaleaf Holdings' Income from Non-Controlling Interests history runs 7 years deep, the most recent figure standing at -$16000.0 for Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests fell 101.96% year-over-year to -$16000.0; the TTM figure through Mar 2026 stood at $2.2 billion (up 71772.83% YoY), while the FY2025 annual figure was $2.9 million, up 144.3% from the prior year.
- Income from Non-Controlling Interests was -$16000.0 for Q1 2026 at Curaleaf Holdings, down from $2.2 billion in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $2.2 billion in Q4 2025 to a low of -$2.7 billion in Q1 2024.
- Historically, Income from Non-Controlling Interests has averaged -$209.2 million across 5 years, with a median of -$1.2 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Income from Non-Controlling Interests slumped 99941.36% in 2023, then soared 241858.24% in 2025.
- A 5-year view of Income from Non-Controlling Interests shows it stood at -$2.4 million in 2022, then plunged by 99941.36% to -$2.4 billion in 2023, then soared by 99.96% to -$910000.0 in 2024, then jumped by 241858.24% to $2.2 billion in 2025, then sank by 100.0% to -$16000.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$16000.0 (Q1 2026), $2.2 billion (Q4 2025), and -$445000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 22.56 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Curaleaf Holdings | - | - | 157.29 Mn | -16,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16,000.00 |
| Dec 31, 2025 | 2.20 Bn |
| Jun 30, 2025 | -445,000.00 |
| Mar 31, 2025 | 817,000.00 |
| Dec 31, 2024 | -910,000.00 |
| Sep 30, 2024 | -2.03 Mn |
| Jun 30, 2024 | -945,000.00 |
| Mar 31, 2024 | -2.70 Bn |
| Dec 31, 2023 | -2.42 Bn |
| Sep 30, 2023 | -1.38 Mn |
| Jun 30, 2023 | -3.25 Mn |
| Dec 31, 2022 | -2.42 Mn |
| Sep 30, 2022 | -2.77 Mn |
| Jun 30, 2022 | 127,000.00 |
| Dec 31, 2021 | -2.54 Mn |
| Sep 30, 2021 | -2.36 Mn |
| Jun 30, 2021 | -1.84 Mn |
| Mar 31, 2021 | 363.00 |
| Dec 31, 2020 | 165.00 |
| Jun 30, 2020 | 193.00 |